Abstract
Calcipotriol and Prednicarbate are widely used effective treatments for psoriasis vulgaris. Combined therapy is known to be superior to monotherapy, but the drug substance degrades when mixed together. The purpose of the study was to develop a formulation which combines Calcipotriol and Prednicarbate in a single vehicle hereby with optimal drug delivery into the skin. As the two substances are incompatible in aqueous and alcoholic medias, different non-aqueous formulations were prepared with suitable solvents and antioxidants. Formulations based on DPPG had no overall effect on skin permeability. However, A 5% polyoxypropylene-15 stearyl ether (PSE) formulation had a marked effect, resulted in a permeation rate comparable to the marketed combination product Diavobet (Calcipotriol and Betamethasone ointment). Thus, by using PSE as solvent, it was possible to combine Calcipotriol and Prednicarbate in a single formulation. Â Keywords: Calcipotriol, Prednicarbate, polyoxypropylene-15 stearyl ether, psoriasis vulgaris.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
